<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81731">
  <stage>Registered</stage>
  <submitdate>21/02/2007</submitdate>
  <approvaldate>26/02/2007</approvaldate>
  <actrnumber>ACTRN12607000145404</actrnumber>
  <trial_identification>
    <studytitle>Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 04.02 - Prospective Study to Determine the Relationships Between Survival and International Federation of Gynecology and Obstetrics (FIGO) Stage, Tumour Volume and Corpus Invasion in relation to prognostic information in patients with Cervical Cancer</scientifictitle>
    <utrn />
    <trialacronym>TROG 04.02</trialacronym>
    <secondaryid>ClinicalTrials.gov: NCT00193934</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer of the uterine cervix</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (Cervix)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Newly diagnosed cervical cancer patients will have key prognostic variables (FIGO stage, tumour diameter, corpus invasion etc) collected at baseline. The treatment received will be documented at the end of treatment and patients will then be followed for first relapse and survival. The duration will be 5 years.</interventions>
    <comparator>No comparator.</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess the prognostic significance, with respect to overall survival, of the factors, FIGO stage.  Overall survival is defined as the date of registration to date of death from any cause. </outcome>
      <timepoint>Patients will be followed up at yearly intervals until death.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the prognostic significance, with respect to overall survival, of the factors, tumour volume. Overall survival is defined as the date of registration to date of death from any cause.</outcome>
      <timepoint>Patients will be followed up at yearly intervals until death.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess the prognostic significance, with respect to overall survival, of the factors, corpus invasion. Overall survival is defined as the date of registration to date of death from any cause.</outcome>
      <timepoint>Patients will be followed up at yearly intervals until death.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess the degree of correlation between maximum clinical diameter of the tumour and primary tumour volume, determined after baseline assessment (time of registration) </outcome>
      <timepoint>The tumour is only measured at this time point. After treatment, only the site and date of first relapse is followed up.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess what relationships exist between FIGO stage, tumour volume and corpus invasion, determined after baseline assessment (time of registration)</outcome>
      <timepoint>The tumour is only measured at this time point. After treatment, only the site and date of first relapse is followed up.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Newly diagnosed, biopsy proven carcinoma of the uterine cervix.- Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.- FIGO Stage Ib IVa.- Maximum clinical tumour diameter recorded.- MRI done within 30 days prior to registration.- Intention to treat radically- Treatment not yet started.- Written informed consent.- Available for follow-up.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Lymphoma, small cell carcinoma and melanoma histology.- Previous hysterectomy- Pregnancy- Prior malignancy excluding basal cell carcinoma (BCC) of the skin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>6/01/2002</anticipatedstartdate>
    <actualstartdate>6/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate>9/06/2009</actualenddate>
    <samplesize>280</samplesize>
    <actualsamplesize>109</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>TROG Cancer Research</primarysponsorname>
    <primarysponsoraddress>c/- Calvary Mater Newcastle
Edith Street
Waratah
NSW
2298</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Royal Australian and New Zealand College of Radiologists</fundingname>
      <fundingaddress>Level 9
51 Druitt Street
SYDNEY NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Auckland Hospital</fundingname>
      <fundingaddress>2 Park Road
Grafton
Auckland 1023</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The researchers propose that it may be corpus invasion, rather than tumour volume per se, which is one of the important determinants of ultimate outcome in cervix cancer. The aim of the proposed prospective, multicentre study, is to confirm the results of our retrospective studies, specifically that corpus invasion or tumour volume or both contribute important prognostic information over and above that provided by the currently used International Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would have important implications for the staging, and management as well as the biologic understanding of the behaviour of cervical cancer.</summary>
    <trialwebsite>www.trog.com.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland Hospital</ethicname>
      <ethicaddress>Multi-Region Ethics Committee
Ministry of Health
180 Molesworth St
PO Box 5013 
Wellington</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress>Christachurch, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dunedin Hospital</ethicname>
      <ethicaddress>Dunedin, Otago, NZ</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>National University Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Singapore</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Calvary Mater Newcastle</ethicname>
      <ethicaddress>Waratah, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate>28/07/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane and Womenâ€™s Hospital</ethicname>
      <ethicaddress>Herston, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress>St Leonards, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Townsville Hospital</ethicname>
      <ethicaddress>Townsville, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress>Wentworthville, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress>Liverpool, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec>2006/108</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Rebecca Montgomery</name>
      <address>TROG Cancer Research
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3911</phone>
      <fax />
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Rebecca Montgomery</name>
      <address>TROG Cancer Research
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3911</phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Cancer Research
Central Operations Office
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3911</phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Farshad Foroudi</name>
      <address>Peter MacCallum Cancer Centre
St Andrew's Place
Melbourne
VIC
3002</address>
      <phone>+61 2 3 96561111</phone>
      <fax />
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>